Metformin PharmConsul
Oral antidiabetic medication (biguanide) for type 2 diabetes mellitus
Metformin PharmConsul contains metformin hydrochloride, a biguanide antidiabetic medication that is considered the first-line pharmacological treatment for type 2 diabetes worldwide. It works by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity. Available as 500 mg film-coated tablets, it is taken by mouth and requires a prescription. Metformin has a well-established safety profile spanning over 60 years of clinical use and is listed on the WHO Model List of Essential Medicines.
Quick Facts
Key Takeaways
- Metformin is the recommended first-line medication for type 2 diabetes according to the WHO, ADA, and NICE guidelines, used when lifestyle changes alone are insufficient
- It does not cause hypoglycaemia (low blood sugar) when used as monotherapy because it does not stimulate insulin secretion
- Gastrointestinal side effects (nausea, diarrhoea) are very common initially but usually subside within weeks; taking it with food helps reduce these effects
- Lactic acidosis is extremely rare but potentially serious — monitor kidney function regularly and stop metformin before procedures involving iodinated contrast media
- Long-term use may reduce vitamin B12 levels, so periodic monitoring of B12 and blood counts is recommended
What Is Metformin PharmConsul and What Is It Used For?
Metformin PharmConsul belongs to the biguanide class of antidiabetic drugs. Its active ingredient, metformin hydrochloride, has been used globally since the late 1950s and remains the most widely prescribed antidiabetic medication in the world. According to the World Health Organization, metformin is included on the Model List of Essential Medicines, underscoring its importance in global diabetes care. It is supplied as 500 mg film-coated tablets intended for oral administration.
Type 2 diabetes mellitus is a chronic metabolic condition characterised by insulin resistance and relative insulin deficiency, leading to persistently elevated blood glucose levels (hyperglycaemia). Over time, uncontrolled hyperglycaemia can cause serious complications affecting the heart, blood vessels, kidneys, eyes, and nerves. Metformin addresses this by working through three main mechanisms: it reduces the amount of glucose produced by the liver (hepatic gluconeogenesis), decreases the absorption of glucose from the gastrointestinal tract, and improves the body's sensitivity to insulin, thereby enhancing peripheral glucose uptake and utilisation.
Unlike sulfonylureas and insulin, metformin does not stimulate insulin release from the pancreas. This means that when used alone (monotherapy), it does not cause hypoglycaemia — a significant advantage for patient safety. Additionally, metformin is weight-neutral or may even be associated with modest weight loss, making it particularly suitable for the many type 2 diabetes patients who are overweight or obese. A landmark clinical trial, the UK Prospective Diabetes Study (UKPDS), demonstrated that metformin reduced diabetes-related mortality by 42% in overweight patients with newly diagnosed type 2 diabetes compared to conventional treatment.
Metformin PharmConsul is typically prescribed as part of a comprehensive treatment plan that includes dietary modifications, regular physical exercise, and weight management. It may be used as monotherapy or in combination with other antidiabetic agents including sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin, depending on the patient's individual glycaemic targets and clinical profile. Current international guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend metformin as the initial pharmacological therapy for most patients with type 2 diabetes.
Beyond glycaemic control, emerging research has explored potential additional benefits of metformin, including possible cardiovascular protective effects and its role in polycystic ovary syndrome (PCOS), though these uses may not be formally approved for all metformin products. Any off-label use should be discussed with and supervised by a qualified healthcare provider.
What Should You Know Before Taking Metformin PharmConsul?
Before initiating treatment with Metformin PharmConsul, a thorough medical evaluation is essential. Your healthcare provider will consider several factors to ensure that metformin is safe and appropriate for your individual circumstances. Understanding the contraindications, warnings, and precautions associated with metformin helps ensure the safest possible use of this medication and allows you to recognise potential problems early.
Contraindications
Metformin PharmConsul should not be taken in the following situations:
- Hypersensitivity: Known allergy to metformin hydrochloride or any of the excipients in the formulation
- Diabetic ketoacidosis or diabetic pre-coma: Metformin is not appropriate for treating diabetic emergencies associated with type 1 diabetes
- Severe renal impairment: Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², due to increased risk of lactic acidosis
- Conditions causing tissue hypoxia: Including cardiac failure, respiratory failure, recent myocardial infarction, and shock, as these increase the risk of lactic acidosis
- Hepatic insufficiency: Severe liver disease impairs lactate clearance
- Acute alcohol intoxication or chronic alcoholism: Alcohol potentiates the effect of metformin on lactate metabolism
- Dehydration: For example from severe or prolonged diarrhoea, vomiting, or fever, as this increases the risk of renal impairment and lactic acidosis
Warnings and Precautions
Lactic acidosis is a very rare but serious metabolic complication. Risk is highest in patients with significantly impaired renal function, uncontrolled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency, or any condition associated with tissue hypoxia. Seek immediate medical attention if you experience rapid breathing, abdominal pain, muscle cramps, general weakness, or hypothermia.
Kidney function monitoring: Renal function should be assessed before starting metformin and at least annually thereafter. In patients with risk factors for renal deterioration (such as elderly patients or those on concurrent nephrotoxic drugs), more frequent monitoring every 3 to 6 months is recommended. The European Medicines Agency (EMA) advises that metformin may be used with appropriate dose adjustments in patients with moderate renal impairment (eGFR 30–59 mL/min/1.73 m²), but should not be initiated in patients with an eGFR below 45 mL/min/1.73 m².
Surgical procedures: Metformin should be discontinued 48 hours before elective surgery involving general, spinal, or epidural anaesthesia and not restarted until at least 48 hours afterwards, or after oral intake has resumed and renal function has been confirmed stable.
Iodinated contrast procedures: Administration of iodinated contrast media during radiological studies can lead to acute kidney injury. Metformin should be stopped at the time of or before the imaging procedure and not restarted until at least 48 hours after, and only after renal function has been re-evaluated and found to be stable.
Pregnancy and Breastfeeding
Metformin crosses the placenta. While some clinical data on the use of metformin during pregnancy exists, primarily in the context of gestational diabetes and PCOS, the standard recommendation is that uncontrolled diabetes during pregnancy increases the risk of congenital malformations and perinatal mortality. Insulin is generally the preferred treatment for diabetes during pregnancy, as it does not cross the placenta. If you are pregnant, planning to become pregnant, or breastfeeding, discuss your treatment options with your healthcare provider.
Metformin is excreted into breast milk in small amounts. While no adverse effects have been reported in breastfed infants, the potential risk should be weighed against the benefit. A decision on whether to discontinue breastfeeding or to discontinue metformin should be made in consultation with your physician.
Always inform your doctor if you have kidney disease, liver problems, heart failure, or if you consume alcohol regularly. These conditions may require dose adjustments or alternative medications. Report any symptoms such as unusual muscle pain, difficulty breathing, unusual sleepiness, or stomach discomfort to your doctor promptly.
How Does Metformin PharmConsul Interact with Other Drugs?
Drug interactions with metformin can affect its efficacy, increase the risk of side effects, or alter blood glucose control. Some interactions are potentially dangerous and require cessation of metformin, while others may need dose adjustment or additional monitoring. The following table summarises the most important drug interactions known for metformin based on European Medicines Agency and FDA labelling information.
Major Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Iodinated contrast media | Risk of acute kidney injury leading to metformin accumulation and lactic acidosis | Stop metformin before procedure; restart 48 hours after if renal function is stable |
| Alcohol | Increased risk of lactic acidosis due to potentiation of metformin's effect on lactate metabolism; also risk of hypoglycaemia | Avoid excessive alcohol intake; avoid binge drinking entirely |
| Insulin & Sulfonylureas | Increased risk of hypoglycaemia when combined with metformin | May require dose reduction of insulin or sulfonylurea; monitor blood glucose closely |
| Loop & Thiazide diuretics | May impair renal function and increase risk of lactic acidosis; some diuretics raise blood glucose | Monitor renal function and blood glucose; adjust doses if necessary |
| NSAIDs (e.g. ibuprofen) | May reduce renal function, leading to metformin accumulation | Use with caution; monitor renal function, especially with prolonged use |
Other Notable Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Corticosteroids (systemic) | May increase blood glucose levels, reducing metformin effectiveness | Monitor blood glucose more frequently; metformin dose may need increasing |
| ACE inhibitors | May lower blood glucose levels, enhancing metformin effect | Monitor blood glucose; may require metformin dose reduction |
| Beta-2 agonists (e.g. salbutamol) | May increase blood glucose via stimulation of glycogenolysis | Monitor blood glucose during concurrent use |
| Cimetidine | Inhibits renal tubular secretion of metformin, increasing plasma concentration by up to 60% | Consider dose adjustment; use alternative H2 antagonist if possible |
| Dolutegravir, Ranolazine, Vandetanib | Inhibit OCT2 transporter, potentially increasing metformin levels | Monitor closely; dose adjustment may be needed |
This list is not exhaustive. Herbal preparations such as bitter melon, fenugreek, and ginseng may also affect blood glucose levels and interact with metformin. Always inform your healthcare provider and pharmacist about all medications, over-the-counter products, and herbal supplements you use before starting or stopping any medication.
What Is the Correct Dosage of Metformin PharmConsul?
The dosage of Metformin PharmConsul must be individualised based on the patient's blood glucose response, tolerability, and renal function. Gradual dose escalation is recommended to minimise gastrointestinal side effects, which are the most common reason for early discontinuation. The tablets should be swallowed whole with a glass of water, taken with or immediately after meals.
Adults
Standard Adult Dosing
Starting dose: 500 mg two or three times daily, or 850 mg once daily, taken with or after meals.
Dose titration: After 10 to 15 days, the dose may be adjusted based on blood glucose measurements. A slow increase in dose improves gastrointestinal tolerability.
Maintenance dose: 1500 mg to 2000 mg per day, taken in two to three divided doses.
Maximum dose: 3000 mg per day in three divided doses (or as directed by your physician).
When used in combination with insulin, the usual starting dose of metformin is 500 mg two to three times daily. The insulin dose is then adjusted based on blood glucose monitoring. It is critical to follow your prescriber's specific instructions regarding dose adjustments when on combination therapy.
Dosage in Renal Impairment
| eGFR (mL/min/1.73m²) | Renal Status | Metformin Dose | Monitoring |
|---|---|---|---|
| ≥60 | Normal to mildly impaired | Full dose (up to 3000 mg/day) | eGFR at least annually |
| 45–59 | Moderate impairment (Stage 3a) | Maximum 2000 mg/day; consider dose reduction | eGFR every 3–6 months |
| 30–44 | Moderate impairment (Stage 3b) | Maximum 1000 mg/day; do not initiate new therapy | eGFR every 3 months |
| <30 | Severe impairment | Contraindicated | Not applicable |
Children and Adolescents
Metformin may be prescribed for children aged 10 years and older with type 2 diabetes. The usual starting dose is 500 mg once daily with a meal, with gradual titration up to a maximum of 2000 mg per day in two to three divided doses. Dose adjustments are based on blood glucose monitoring. Children under 10 years of age should not take metformin unless specifically advised by a paediatric endocrinologist, as safety and efficacy data in this younger age group are limited.
Elderly Patients
In elderly patients (typically aged 65 and older), dosing should be conservative and based on careful assessment of renal function. Kidney function naturally declines with age, and elderly patients are more susceptible to dehydration and renal impairment from intercurrent illness. Regular monitoring of eGFR is essential, and the maximum dose may need to be lower than in younger adults. The starting dose should be the lowest effective dose, typically 500 mg once or twice daily.
Missed Dose
If you miss a dose of Metformin PharmConsul, take it as soon as you remember — provided it is near the usual time for that dose. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one, as this increases the risk of gastrointestinal side effects and could disturb blood glucose control.
Overdose
Hypoglycaemia has not been observed with metformin doses up to 85 g (far exceeding the therapeutic range), although lactic acidosis has occurred in such circumstances. Massive overdose or co-existing risk factors may lead to lactic acidosis, which is a medical emergency. Symptoms include severe nausea, vomiting, diarrhoea, rapid breathing (hyperventilation), abdominal pain, hypothermia, and reduced consciousness. If overdose is suspected, call your local emergency services immediately. Treatment is supportive: metformin is dialysable with a clearance of up to 170 mL/min under good haemodynamic conditions, so haemodialysis may be used to remove accumulated metformin.
What Are the Side Effects of Metformin PharmConsul?
Like all medicines, Metformin PharmConsul can cause side effects, although not everybody gets them. The following side effect frequencies are based on data from clinical trials, post-marketing surveillance, and authoritative references including the EMA Summary of Product Characteristics and the British National Formulary (BNF). Understanding the frequency and nature of these effects helps patients and healthcare providers make informed decisions about treatment.
Very Common
Affects more than 1 in 10 patients
- Nausea
- Vomiting
- Diarrhoea
- Abdominal pain and cramping
- Loss of appetite (anorexia)
Common
Affects 1 in 10 to 1 in 100 patients
- Metallic taste (taste disturbance / dysgeusia)
- Flatulence and bloating
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Skin reactions (rash, itching, urticaria)
- Elevated liver enzymes
Very Rare
Affects fewer than 1 in 10,000 patients
- Lactic acidosis — a potentially life-threatening metabolic emergency
- Vitamin B12 deficiency with prolonged use (may present as megaloblastic anaemia, neuropathy)
- Hepatitis and liver function abnormalities (reversible upon discontinuation)
Gastrointestinal side effects are most frequently encountered during the initiation phase of treatment. They can be significantly reduced by starting with a low dose and increasing it gradually (dose titration), and by always taking metformin with or immediately after meals. In most patients, these symptoms resolve spontaneously within two to four weeks as the body adjusts to the medication.
Vitamin B12 deficiency: Long-term treatment with metformin (typically more than 3 to 5 years) has been associated with decreased absorption of vitamin B12. This may lead to clinically significant deficiency in some patients, particularly those with inadequate dietary B12 intake. The American Diabetes Association recommends periodic monitoring of B12 levels in patients on long-term metformin therapy, especially those with anaemia or peripheral neuropathy.
Lactic acidosis: This is the most feared adverse effect of metformin, though its incidence is extremely low (estimated at 3 to 10 per 100,000 patient-years). It occurs almost exclusively in patients with predisposing factors such as severe renal impairment, heart failure, hepatic disease, sepsis, or dehydration. With proper patient selection and adherence to prescribing guidelines, the risk is minimal. If you develop unexplained rapid breathing, persistent nausea, abdominal pain, or muscle cramps while taking metformin, seek immediate medical attention.
Contact your healthcare provider if gastrointestinal side effects persist beyond several weeks, if you develop signs of vitamin B12 deficiency (unusual tiredness, pale skin, tingling in hands or feet), or if you notice any new or worsening symptoms. Seek emergency medical help for symptoms of lactic acidosis: rapid or difficult breathing, unusual drowsiness, abdominal pain with muscle cramping, or feeling very cold.
How Should You Store Metformin PharmConsul?
Proper storage of medications is essential to maintain their effectiveness and safety. Metformin PharmConsul film-coated tablets should be stored at temperatures not exceeding 25°C (77°F). Keep the tablets in their original blister pack or container to protect them from moisture, which can degrade the active ingredient. Do not store in the bathroom or near sinks where humidity is high.
Always check the expiry date printed on the packaging before taking any medication. Do not use Metformin PharmConsul after the expiry date (indicated as "EXP" on the carton and blister). The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. Return unused or expired medicines to your pharmacy for safe disposal. This helps protect the environment and prevents accidental ingestion by children or animals.
- Store below 25°C (77°F)
- Keep in original packaging to protect from moisture
- Keep out of the sight and reach of children
- Do not use after the expiry date
- Do not dispose of via wastewater or household waste
What Does Metformin PharmConsul Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. Metformin PharmConsul 500 mg film-coated tablets contain the following:
Active substance: Each tablet contains 500 mg of metformin hydrochloride, equivalent to approximately 390 mg of metformin base.
Excipients (inactive ingredients): The tablet core typically contains povidone (a binding agent), magnesium stearate (a lubricant), and other standard pharmaceutical excipients. The film coating may contain hypromellose, macrogol, and titanium dioxide, which give the tablet its smooth white appearance and make it easier to swallow. The exact excipient composition may vary; refer to the patient information leaflet included with your specific product for the complete list.
Appearance: Metformin PharmConsul 500 mg tablets are white, round or oval-shaped film-coated tablets. They may have a score line to facilitate dose adjustment if necessary, though this should only be done on the advice of your healthcare provider.
If you have lactose intolerance, coeliac disease, or other dietary sensitivities, consult your pharmacist or doctor to confirm that the excipients in Metformin PharmConsul are suitable for you. Metformin tablets are generally lactose-free and gluten-free, but this should always be verified against the specific product information.
Frequently Asked Questions
Metformin PharmConsul is a prescription medication used primarily for the treatment of type 2 diabetes mellitus. It helps control blood sugar levels by reducing the amount of glucose produced by the liver, decreasing glucose absorption in the intestines, and improving the body's sensitivity to insulin. It is typically used when diet and exercise alone are not sufficient to control blood glucose levels, and is recommended as the first-line pharmacological therapy by major international diabetes guidelines.
The most common side effects of metformin are gastrointestinal disturbances: nausea, vomiting, diarrhoea, abdominal pain, and loss of appetite. These affect more than 1 in 10 patients and typically occur at the start of treatment. They usually improve within a few weeks. Taking metformin with or immediately after meals and starting with a low dose can significantly reduce these effects. A metallic taste in the mouth is also commonly reported.
When used alone (monotherapy), metformin does not typically cause hypoglycaemia because it does not stimulate insulin secretion from the pancreas. However, the risk of low blood sugar increases when metformin is combined with other antidiabetic medications such as sulfonylureas or insulin. Patients on combination therapy should be aware of the signs of hypoglycaemia (shakiness, sweating, confusion, rapid heartbeat) and discuss appropriate monitoring and management strategies with their healthcare provider.
Lactic acidosis is a very rare but potentially life-threatening metabolic condition characterised by a build-up of lactic acid in the blood. It occurs in fewer than 1 in 10,000 metformin users but carries a high mortality rate when it does occur. Risk factors include severe kidney disease, liver disease, dehydration, excessive alcohol consumption, and conditions causing tissue hypoxia (e.g., heart failure, severe infection). Symptoms include rapid breathing, abdominal pain, muscle cramps, and general malaise. Seek emergency medical attention immediately if you experience these symptoms.
Yes, metformin must be discontinued at the time of or before the procedure involving iodinated contrast media (such as certain CT scans or angiograms). It should not be restarted until at least 48 hours after the procedure, and only after renal function has been re-evaluated and found to be stable. This precaution is necessary because contrast dye can temporarily affect kidney function, and impaired kidney function increases the risk of lactic acidosis in patients taking metformin. Always inform the radiology team that you are taking metformin before any imaging procedure.
No, metformin is generally considered weight-neutral and may even be associated with modest weight loss. This is one of the advantages of metformin compared to some other antidiabetic medications such as sulfonylureas, thiazolidinediones, and insulin, which can cause weight gain. The UKPDS trial showed that metformin-treated patients did not experience significant weight gain. This weight-neutral profile makes metformin particularly suitable for overweight and obese patients with type 2 diabetes.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: World Health Organization; 2023. Available at: who.int
- European Medicines Agency (EMA). Metformin Hydrochloride — Summary of Product Characteristics. European Medicines Agency; 2024. Available at: ema.europa.eu
- American Diabetes Association (ADA). Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1). Available at: doi.org/10.2337/dc25-SINT
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]. Updated 2024. Available at: nice.org.uk
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the ADA and EASD. Diabetes Care. 2015;38(1):140-149. doi:10.2337/dc14-2441
- British National Formulary (BNF). Metformin hydrochloride. National Institute for Health and Care Excellence; 2025. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Metformin Hydrochloride Tablets — Prescribing Information. 2024. Available at: fda.gov
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754
- DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):541-549. doi:10.1056/NEJM199508313330902
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team in accordance with our editorial standards.
Medical Content
iMedic Medical Writers — Clinical Pharmacology & Endocrinology
Medical Review
iMedic Medical Review Board — Independent Expert Panel
Fact Checking
Cross-referenced with EMA SmPC, FDA label, BNF, and WHO Essential Medicines
Evidence Standard
Level 1A — Systematic reviews and meta-analyses of RCTs (GRADE framework)
Last medical review: | Next scheduled review: